Today: 19 July 2026
The Trade Desk (TTD) Stock Price Falls 6% Again as Publicis Rift Triggers Wall Street Downgrades
18 March 2026
1 min read

The Trade Desk (TTD) Stock Price Falls 6% Again as Publicis Rift Triggers Wall Street Downgrades

NEW YORK, March 18, 2026, 17:28 EDT

The Trade Desk tumbled for a second straight session Wednesday, falling 6.1% to $23.55 by 5:11 p.m. EDT, after Publicis Groupe pulled its endorsement of the ad-tech platform for clients. Tuesday saw shares lose 7.4%. Analysts followed up by slashing ratings and price targets.

Here’s why it matters: agency relationships are core to Trade Desk’s business. The most recent annual report spells it out—if you aggregate client accounts by parent company, two ad holding companies would each account for over 10% of 2025 gross billings. Combined, that’s 30%.

This dispute comes as Trade Desk navigates some internal change. Back in January, Alex Kayyal was out as CFO and Tahnil Davis stepped in as interim finance head. A month later, the company projected at least $678 million in first-quarter revenue, coming off a 2025 annual revenue mark of $2.9 billion.

Publicis told clients that an independent auditor found Trade Desk “did not pass the audit” and advised those under its master services agreement to steer clear of the platform. According to ADWEEK, the memo claimed Trade Desk rolled its demand-side platform fee into additional charges and tacked on certain tools without disclosing client approval. Adweek

Trade Desk shot down the account. Statements published by MARKETING-INTERACTIVE and on LinkedIn show the company arguing the audit request would have forced disclosure of data protected by customer and partner confidentiality. Chief Executive Jeff Green added that TTD has never “failed” an audit. Marketing-Interactive

Wall Street didn’t wait. Barron’s noted Rosenblatt’s Barton Crockett downgraded the stock to neutral, trimming his target to $25. Stifel’s Mark Kelley also cut to hold, now aiming for $26, citing “no clear near-term catalyst” to lift sentiment. Both analysts pointed to the risk: advertisers could steer spending toward Google’s DV360 or Amazon’s rival platform—tools that automate digital ad buys. Barron’s

Even after LinkedIn rolled out new product details with Trade Desk, the stock slid further. Marketers can now pick up LinkedIn’s connected-TV ads—streaming TV, that is—directly or programmatically through The Trade Desk using Microsoft Monetize, according to LinkedIn. Didn’t matter; shares continued to drop.

Sizing up the revenue impact isn’t straightforward. Jefferies analyst James Heaney points out the uncertainty: it’s not clear if Publicis will yank spending right away, hit pause, renegotiate terms, or just scrutinize accounts one by one. Trade Desk notes in its latest annual report that most of its deals don’t guarantee major ad budgets, and can be scrapped with just 60 days’ notice.

Green stepped in with a show of confidence, picking up 6 million shares over March 2 to March 4, according to a Form 4 he filed with the SEC. He paid weighted averages from $23.49 up to $25.08. By Wednesday, the stock had slipped to $23.55—right back near the bottom of that purchase range.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
Gold Price Today Falls as Dollar Rises, but Fed and Oil Shock Keep Bullion in Play
Previous Story

Gold Price Today Falls as Dollar Rises, but Fed and Oil Shock Keep Bullion in Play

Gold Price Today: Bullion Steadies Near $4,400 After Monday’s Violent Selloff
Next Story

Gold Price Today: Bullion Steadies Near $4,400 After Monday’s Violent Selloff

Go toTop